Xilio Therapeutics (XLO) Total Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $34.2 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 35.79% year-over-year to $34.2 million; the TTM figure through Jun 2026 stood at $34.2 million (down 35.79% YoY), while the FY2025 annual figure was $56.3 million, up 106.42% from the prior year.
• Total Current Liabilities came in at $34.2 million for Q2 2026 at Xilio Therapeutics, down from $43.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $56.4 million in Q3 2025 to a low of $12.2 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $31.1 million, with a median of $29.4 million recorded in 2024.
• Year-over-year, Total Current Liabilities surged 137.16% in 2024 and slumped 35.79% in 2026.
• Over 5 years, Total Current Liabilities stood at $21.1 million in 2022, then fell by 24.44% to $16.0 million in 2023, then surged by 70.84% to $27.3 million in 2024, then jumped by 106.42% to $56.3 million in 2025, then sank by 39.23% to $34.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $34.2 million in Q2 2026, $43.0 million in Q1 2026, and $56.3 million in Q4 2025.